On June, 6 Organovo Holdings, Inc. (ONVO) EPS Estimated At $-0.07

May 17, 2018 - By Alice Reed

Organovo Holdings, Inc. (NASDAQ:ONVO) Corporate Logo
Big Money Sentiment decreased to 0.67 in 2017 Q4. It has change of 0.86, from 2017Q3’s 1.53. The ratio worsened due to Organovo Holdings, Inc. positioning: 16 sold and 38 reduced. 18 funds acquired holdings and 18 increased holdings. Investors holded 24.05 million in 2017Q3 but now own 20.74 million shares or 13.74% less.
Voya Mngmt Ltd Liability Corporation, Georgia-based fund reported 52,032 shs. Deltec Asset Mngmt Limited Liability Corp invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Cetera Advsrs Lc has invested 0% of its capital in Organovo Holdings, Inc. (NASDAQ:ONVO). Lehman Resource holds 0.11% or 161,000 shs. Raymond James Svcs Advsr Inc has invested 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Peconic Partners Ltd Liability holds 0% or 24,000 shs in its capital. Paloma Prtn Mgmt reported 97,292 shs. Lpl Llc stated it has 0% in Organovo Holdings, Inc. (NASDAQ:ONVO). Fin Gru has 251,500 shs. Geode Cap Mgmt Limited Liability Company holds 949,650 shs. Rhumbline Advisers reported 89,789 shs stake. Virtu Finance Ltd Llc invested in 35,280 shs or 0% of the stock. Renaissance Technology invested 0% of its capital in Organovo Holdings, Inc. (NASDAQ:ONVO). California State Teachers Retirement Systems has invested 0% of its capital in Organovo Holdings, Inc. (NASDAQ:ONVO). Iconiq Limited Liability Company reported 13,100 shs.

On June, 6 WallStreet awaited Organovo Holdings, Inc. (NASDAQ:ONVO)’s earnings release, RTT reports. This year’s EPS analyst estimate is awaited to be $-0.07. That is 30.00 % up compareed to $-0.1 EPS for last year. After $-0.07 EPS was revealed previous quarter, analysts now see EPS growth of 0.00 % for Organovo Holdings, Inc.. The stock decreased 2.30% or $0.04 during the last trading session, touching $1.7.Organovo Holdings, Inc. has 2.45M shares volume, 167.54% up from normal. ONVO is downtrending and has moved 67.42% since May 17, 2017. The stock underperformed the S&P500 by 78.97%.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications.The company has $188.42 million market cap. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners.Last it reported negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were posted by Globenewswire.com, Nasdaq.com and Globenewswire.com. The first one has “Organovo and Samsara Sciences Partner with New Manufacturing USA Institute” as a title and was posted on May 03, 2018. The next is “Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results” on May 14, 2018. And last was posted on May 16, 2018, called “New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals …”.

Organovo Holdings, Inc. (NASDAQ:ONVO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: